Status: Not Enrolling
ClinicalTrials.gov Identifier: NCT02302989
Pro-Con: Prospective double-blind randomized study to evaluate Lucentis for prophylaxis against the conversion to neovascular age-related macular degeneration (AMD in high-risk eyes)
Condition: AMD in Fellow Eye
Study Type: Interventional
Duration: 24 months
Eligibility:
For additional information, please click here
Back to Clinical Research